Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of an adsorbed acellular pertussis (three-component), diphtheria, and tetanus combined vaccine in infants aged 2 or 3 months
CTR20191673Phase 3Active
- Sponsor
- CanSino Biologics Inc.
- Start
- Aug 2023
- Countries
- 1
01
Overview
A Phase 3 trial of diphtheria, tetanus, and acellular pertussis vaccine in pertussis, diphtheria, Tetanus, sponsored by CanSino Biologics Inc.. Started Aug 2023; status: active.
02
Drugs
diphtheria, tetanus, and acellular pertussis vaccine
03
Conditions
pertussisdiphtheriaTetanus
Beyond the preview
Go deeper on CTR20191673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191673.